Please use this identifier to cite or link to this item:
https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/4212
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Klein, O | - |
dc.contributor.author | Gao, B | - |
dc.contributor.author | Michael, M | - |
dc.contributor.author | Zielinski, R | - |
dc.contributor.author | So, J | - |
dc.contributor.author | Harris, S.J | - |
dc.contributor.author | Kee, D | - |
dc.contributor.author | Collins, I.M | - |
dc.contributor.author | Lam, W-S | - |
dc.contributor.author | Lyle, M | - |
dc.contributor.author | Underhill, C.R | - |
dc.contributor.author | Brown, M | - |
dc.contributor.author | Wong, S.F | - |
dc.contributor.author | Palmer, J.B | - |
dc.contributor.author | Thomas, D | - |
dc.contributor.author | Wilkie, K | - |
dc.contributor.author | Cebon, J | - |
dc.contributor.author | Carlino, M.S | - |
dc.date.accessioned | 2024-09-22T23:14:18Z | - |
dc.date.available | 2024-09-22T23:14:18Z | - |
dc.date.issued | 2024-09 | - |
dc.identifier.uri | https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/4212 | - |
dc.description.abstract | Mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) cancers (ca) are one of the most immunogenic ca. Anti-PD-1 monotherapy using Pembrolizumab has regulatory approval in advanced MSI-H colorectal ca (CRC) and non-CRCs leading to durable responses in a 1/3 of pts. Combined anti-PD-1/CTLA-4 blockade using nivolumab (nivo) and ipilimumab (ipi) has shown superiority to anti-PD-1 monotherapy in other immunogenic ca such as melanoma. MoST-CIRCUIT is the first trial that investigated combined anti-PD-1/CTLA-4 blockade in advanced dMMR/MSI-H non-CRCs. | en |
dc.subject | Cancer | en |
dc.subject | Nivolumab | en |
dc.subject | Ipilimumab | en |
dc.subject | dMMR/MSI-H noncolorectal cancers | en |
dc.subject | MoST-CIRCUIT | en |
dc.title | 998MO Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study | en |
dc.type | Conference Paper | en |
dc.identifier.journaltitle | Annals of Oncology | en |
dc.description.conferencename | ESMO Congress 2024 | - |
dc.accession.number | https://doi.org/10.1016/j.annonc.2024.08.1057 | en |
dc.identifier.url | https://www.annalsofoncology.org/article/S0923-7534(24)02576-6/fulltext | en |
dc.format.startpage | S679 | en |
dc.source.volume | 35 | en |
dc.format.pages | S679 - S680 | en |
dc.identifier.importdoi | https://doi.org/10.1016/j.annonc.2024.08.1057 | en |
dc.identifier.date | 2024-09 | - |
dc.contributor.swhauthor | Collins, Ian M. | - |
Appears in Collections: | SWH Staff Publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.